返回 Agenda
Session Chair(s)
Susan Martin
Head, Patient Reported Outcomes
RTI Health Solutions, United States
Speaker(s)
1:00-1:05PM Welcome/Overview
Susan Martin
RTI Health Solutions, United States
Head, Patient Reported Outcomes
1:05-1:25PM Commercial Considerations for Study Endpoints in RD
Harris Kaplan, MBA
Red Team Associates, Div of Healogix, United States
Managing Partner
1:25-1:45PM Clinical Challenges and Opportunities in Study Endpoint Development for RD
Annabel Barbier, MD, PhD
Agios Pharmaceuticals Inc, United States
Vice President, Clinical Development Rare Genetic Diseases
1:45-2:10PM Regulatory Considerations for Clinical Outcome Assessment Selection in RD
Elektra Papadopoulos, MD, MPH
AbbVie, United States
Director, Patient Experience Data and Strategy
2:10PM-2:25PM Networking Break
All Participants
United States
2:25-2:50PM RD Endpoint Strategy and Implementation
Linda S. Deal, MS
Pfizer Inc., United States
Head of Patient-Centered Outcomes Measurement
2:50-3:10PM Working with Patient Advocacy Organizations to Implement a RD Strategy
Marianne Clancy, MPA
Cure HHT, United States
Executive Director
3:10-3:45PM RD Endpoint Evaluation, Analysis and Interpretation
Lori McLeod, PhD
RTI Health Solutions, United States
Head, Psychometrics
3:45-4:20PM Panel Discussion: All Session Speakers and Additional Panelist
Lawrence Charnas, MD, PhD
Novartis Institutes For Biomedical Research, United States
Senior Translational Medicine Expert Musculoskeletal Diseases
4:20-4:30PM Wrap-up/Session Adjourned
Susan Martin
RTI Health Solutions, United States
Head, Patient Reported Outcomes